ArticleFrontiers in oncology2018
A Comparative Study of Primary Adenoid Cystic and Mucoepidermoid Carcinoma of Lung.
Article in Frontiers in oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- The clinical outcomes and overall survival in patients with mucoepidermoid and adenoid cystic carcinoma of the salivary glands: A comparative analysis of long-term outcomes.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Clinicopathological and Prognostic Comparison of Primary Pulmonary Adenoid Cystic Carcinoma and Mucoepidermoid Carcinoma: A Single-Center Study.Journal of clinical medicine · 2026Article
- Bronchoscopy, surgery and radiation therapy for bronchial adenoid cystic carcinoma: A retrospective cohort study.Rare tumors · 2026Article
- A surgical strategy-based nomogram for primary pulmonary mucoepidermoid carcinoma.Discover oncology · 2025Article
- [Clinical Characteristics, MAML2 Gene Rearrangement and Prognosis of Pulmonary Mucoepidermoid Carcinoma].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Article
- Clinical, laboratory, pathological, and radiological characteristics and prognosis of patients with pulmonary salivary gland-type tumors.Journal of cancer research and clinical oncology · 2023Article
- Pulmonary adenoid cystic carcinoma: molecular characteristics and literature review.Diagnostic pathology · 2023Review
- Pulmonary mucoepidermoid carcinoma: A clinicopathological study of 45 patients.Thoracic cancer · 2022Article
- Pulmonary Salivary Gland Tumor, Mucoepidermoid Carcinoma: A Literature Review.Journal of oncology · 2022Review
- [Survival Analysis of 76 Cases of Head and Neck Adenoid Cystic Carcinoma with Lung Metastasis].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2021Article
- Article
- Dyspnea, focal wheeze, and a slow growing endobronchial tumor.Respiratory medicine case reports · 2021Article
- Curious case of primary pulmonary mucoepidermoid carcinoma.Journal of family medicine and primary care · 2019Article
- Article
- Radiological and Clinical Features and Outcomes of Patients with Primary Pulmonary Salivary Gland-Type Tumors.Canadian respiratory journal · 2019Article
- A rare case of endobronchial mucoepidermoid carcinoma of the lung presenting as non-resolving pneumonia.Respiratory medicine case reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary mucoepidermoid carcinoma (PMEC) and pulmonary adenoid cystic carcinoma (PACC) are the two major types of primary salivary gland-type (PSGT) lung cancers. The demographic profile, clinicopathological features, and predictors of survival as an overall group have not been described for PSGT cancers of lung.
methodsIn this study, we analyzed demographic, clinical, and survival data from 1,032 patients (546 PMEC and 486 PACC) who were diagnosed of PSGT lung cancer in the Surveillance, Epidemiology and End Results database from 1973 to 2014.
resultsThe PSGT constituted 0.09% of all lung cancers with age-adjusted incidence rate of 0.07 per 100,000 person-years and change of -32% from 1973 to 2014. The incidence of PMEC was slightly higher than PACC but there were no differences in the age and sex distribution. PACCs (55%) were significantly higher at trachea and main bronchus while PMECs were more common at peripheral lungs (85%). Most of the tumors were diagnosed at an early stage and were low grade irrespective of histology. As compared to PMEC, significantly higher number of patients with PACC underwent radical surgery and received adjuvant radiation. The 1- and 5-year cause-specific survival was 76.6 and 62.8%, respectively. On multivariate analysis, the survival was affected by age at diagnosis, tumor stage, histological grade, period of diagnosis, and surgical resection. The histology showed strong interaction with time and hazard ratio of patients with PACC was significantly worse than patients with PMEC only after 5 years.
conclusionThe incidence of pulmonary PSGT cancer is 7 cases per 10 million population in the United States and is decreasing. There was no difference between demographic profile of patients with PMEC and PACC but pathological features were diverse. The difference in the survival of patients with the two histological types surfaced only after 5 years when survival of patients with PMEC was better than PACC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.